KX2-391 Dihydrochloride: Dual Src Kinase & Tubulin Inhibitor for Advanced Research

Executive Summary: KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) is a first-in-class dual Src kinase and tubulin polymerization inhibitor with nanomolar potency and high selectivity (Smolinski et al., DOI:10.1021/acs.jmedchem.8b00164). It disrupts oncogenic signaling by binding the Src substrate site and interferes with the tubulin cytoskeleton via a novel α-β heterodimer site. The compound demonstrates anti-HBV activity by suppressing precore promoter-driven viral transcription and inhibits botulinum neurotoxin A (BoNT/A) via SNAP-25 cleavage blockade. Supplied by APExBIO, KX2-391 dihydrochloride is well characterized for oncology, virology, and neurotoxin research (see product page), with robust in vitro and in vivo benchmarks. Clinical use includes topical treatment for actinic keratosis and oral regimens for tumors, with favorable tolerability and minimal peripheral neuropathy.

Biological Rationale

Src kinase is a nonreceptor tyrosine kinase involved in tumor growth, metastasis, and cell motility. Overactivation of Src signaling is observed in various cancers, making it a prime target for anticancer drug development (DOI:10.1021/acs.jmedchem.8b00164). Traditional ATP-competitive Src inhibitors often exhibit poor selectivity and limited efficacy in solid tumors. Dual targeting of Src and tubulin polymerization introduces synergistic disruption of both signaling and structural pathways vital for tumor proliferation and migration. Furthermore, the HBV replication pathway relies on host transcription factors modulated by Src and cytoskeletal dynamics, while BoNT/A neurotoxicity involves SNAP-25 cleavage, a process susceptible to tubulin network perturbation. KX2-391 dihydrochloride bridges these mechanisms, supporting its use in cancer biology, anti-HBV research, and neurotoxin inhibition (Q-VD.com; this article extends previous reviews by detailing translational integration and quantitative benchmarks).

Mechanism of Action of KX2-391 dihydrochloride

KX2-391 dihydrochloride (also known as KX-01 dihydrochloride or Tirbanibulin dihydrochloride) exerts its effects through two primary mechanisms:

• Src kinase inhibition: KX2-391 binds to the peptide substrate-binding site of Src, not the ATP site, conferring high selectivity and nanomolar potency (IC₅₀ = 23 nM in NIH3T3/c-Src527F cells, 39 nM in SYF/c-Src527F cells).
• Tubulin polymerization inhibition: It binds a unique site on the α-β tubulin heterodimer, disrupting microtubule assembly at concentrations ≥80 nM, leading to cytoskeletal destabilization (DOI).

Beyond these, KX2-391 inhibits hepatitis B virus (HBV) transcription by targeting the precore promoter and blocks botulinum neurotoxin A (BoNT/A) activity by interfering with the light chain's ability to cleave SNAP-25. These mechanisms have been validated in pathway-specific assays and animal models (A-317491.com; this article updates mechanistic depth for current workflows).

Evidence & Benchmarks

• KX2-391 dihydrochloride inhibits Src kinase in cell-based assays with IC₅₀ values of 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F) (Smolinski et al., 2018).
• Tubulin polymerization is inhibited at concentrations ≥80 nM in vitro, distinct from classic colchicine or Vinca sites (Smolinski et al., 2018).
• Anti-HBV activity is demonstrated with EC₅₀ = 0.14 μM in PXB cells and 2.7 μM in HepG2-NTCP cells (APExBIO).
• BoNT/A protease inhibition occurs at 10–40 μM, preventing SNAP-25 cleavage in neuronal assays (Smolinski et al., 2018).
• In vivo, oral dosing in mice (5–15 mg/kg once/twice daily) and chimpanzees (1 mg/kg twice daily) achieves therapeutic plasma levels for anti-HBV and anticancer effects (Smolinski et al., 2018).
• KX2-391 dihydrochloride is clinically used as a 1% topical ointment for actinic keratosis and orally at 40–120 mg/day for tumors (Smolinski et al., 2018).
• No significant peripheral neuropathy or severe adverse events reported in clinical trials (Smolinski et al., 2018).

For further experimental optimization, Optimizing Cell-Based Assays with KX2-391 Dihydrochloride provides real-world protocol guidance; this article clarifies dosing and tolerability across multiple applications.

Applications, Limits & Misconceptions

KX2-391 dihydrochloride is validated for:

• Cancer research: Src signaling and tubulin cytoskeleton targeting in preclinical and clinical studies.
• Virology: Suppression of HBV transcription at submicromolar EC₅₀ values.
• Neurotoxin research: Inhibition of BoNT/A protease activity.

It is not a broad-spectrum kinase inhibitor and should not be used where ATP-competitive inhibition is required. Its insolubility in water limits certain in vivo applications. For a systems biology perspective, see KX2-391 Dihydrochloride: Mechanistic Insights and Pathway Integration; this article extends those insights by mapping concentrations to outcomes.

Common Pitfalls or Misconceptions

• KX2-391 dihydrochloride does not inhibit all tyrosine kinases—its selectivity is for the Src family via the substrate site.
• It does not act as a classic ATP-site kinase inhibitor; using it in ATP-competitive screens may yield false negatives.
• Water solubility is poor; dissolution should be in DMSO (≥25.2 mg/mL) or ethanol (≥48.8 mg/mL with gentle warming).
• Anti-HBV activity is specific to transcriptional suppression and not viral entry or capsid assembly steps.
• BoNT/A inhibition requires higher micromolar concentrations (10–40 μM); lower doses are insufficient for neurotoxin blockade.

Workflow Integration & Parameters

In vitro: For Src or anticancer assays, use 0.013–10 μM concentration ranges; anti-HBV studies use up to 10 μM. For BoNT/A assays, 10–40 μM is required. Ensure DMSO or ethanol as solvent.
In vivo: Administer orally at 5–15 mg/kg in mice (once/twice daily) or 1 mg/kg twice daily in chimpanzees. Maintain storage at -20°C.
Clinical translation: Topical 1% ointment (10 mg/g) is approved for actinic keratosis; oral regimens (40–120 mg/day) trialed for cancer.
Reproducibility: APExBIO's standardized material (SKU A3535) maximizes lot-to-lot consistency; see the product page for current QC data.

Conclusion & Outlook

KX2-391 dihydrochloride represents a paradigm shift in dual mechanism inhibition, combining precise Src substrate-site blockade with cytoskeletal disruption. Its broad preclinical and clinical validation across cancer, HBV, and neurotoxin models, coupled with excellent tolerability, marks it as a key tool for translational research. Ongoing studies may expand its application spectrum, but users should adhere to validated parameters for optimal outcomes. This article clarifies dosage, selectivity, and mechanistic boundaries, extending the translational guidance presented in KX2-391 Dihydrochloride: A Translational Game-Changer by mapping dose-response relationships and practical workflow tips.